Impact of anti-inflammatory nutrients on obesity-associated metabolic-inflammation from childhood through to adulthood

Proceedings of the Nutrition Society

Volumn 75, Issue 2, 2016, Pages 115-124

  Connaughton, Ruth M ^a   McMorrow, Aoibheann M ^a   McGillicuddy, Fiona C ^b   Lithander, Fiona E ^c   Roche, Helen M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Anti inflammatory nutrients; Metabolic health; Obesity

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; EPIGALLOCATECHIN GALLATE; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 6; LYCOPENE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALSALATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VITAMIN D; ANTIINFLAMMATORY AGENT;

ADIPOSE TISSUE; ADULTHOOD; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CELL INFILTRATION; CHILDHOOD; COMORBIDITY; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE ASSOCIATION; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT SELECTION; PERSONALIZED MEDICINE; PREVALENCE; ADOLESCENT; ADULT; CARDIOVASCULAR DISEASES; CHILD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIET; IMMUNOLOGY; MACROPHAGE; NUTRITION; PATHOPHYSIOLOGY; T LYMPHOCYTE;

ADIPOSE TISSUE; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR DISEASES; CHILD; DIABETES MELLITUS, TYPE 2; DIET; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGES; NUTRITION THERAPY; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; OBESITY; PRECISION MEDICINE; T-LYMPHOCYTES;

EID: 84960104728     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665116000070     Document Type: Article

References (116)

1. Lumeng CN &Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest Am Soc Clin Invest 121, 2111-2117.
2. DeBoer MD (2013) Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions. Nutrition 29, 379-386.
3. McMorrow AM, Connaughton RM, Lithander FE et al. (2015) Adipose tissue dysregulation and metabolic consequences in childhood and adolescent obesity: potential impact of dietary fat quality. Proc Nutr Soc 74, 67-82.
4. World Health Organization (2015) WHO|Obesity and Overweight. Available at www.who.int/mediacentre/actsheets/ fs311/en/.
5. Juonala M, Magnussen CG, Berenson GS et al. (2011) Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med 365, 1876-1885.
6. Reilly JJ &Kelly J (2011) Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic review. Int J Obes (Lond) 35, 891-898.
7. Weiss R, Dziura J, Burgert TS et al. (2004) Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350, 2362-2374.
8. McGovern L, Johnson JN, Paulo R et al. (2008) Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. J Clin Endocrinol Metab 93, 4600-4605.
9. Kahn BB &Flier JS (2000) Obesity and insulin resistance. J Clin Invest 106, 473-481.
10. Olefsky JM &Glass CK (2010) Macrophages, inflammation, and insulin resistance. Ann Rev Physiol 72, 219-246.
11. Saltiel AR &Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799-806.
12. Schenk S, Saberi M &Olefsky JM (2008) Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 118, 2992-3002.
13. Graham TE &Kahn BB (2007) Tissue-specific alterations of glucose transport and molecular mechanisms of intertissue communication in obesity and type 2 diabetes. Horm Metab Res 39, 717-721.
14. Hirashima Y, Tsuruzoe K, Kodama S et al. (2003) Insulin down-regulates insulin receptor substrate-2 expression through the phosphatidylinositol 3-kinase/Akt pathway. J Endocrinol 179, 253-266.
15. Shimomura I, Matsuda M, Hammer RE et al. (2000) Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6, 77-86.
16. Caperuto LC, Anhê GF, Amanso AM et al. (2006) Distinct regulation of IRS proteins in adipose tissue from obese aged and dexamethasone-treated rats. Endocrine 29, 391-398.
17. Taniguchi CM, Emanuelli B &Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7, 85-96.
18. Hirosumi J, Tuncman G, Chang L et al. (2002) A central role for JNK in obesity and insulin resistance. Nature 420, 333-336.
19. De Luca C &Olefsky JM (2008) Inflammation and insulin resistance. FEBS Lett 582, 97-105.
20. Calay ES &Hotamisligil GS (2013) Turning off the inflammatory, but not the metabolic, flames. Nat Med 19, 265-267.
21. Lasselin J, Magne E, Beau C et al. (2014) Adipose inflammation in obesity: relationship with circulating levels of inflammatory markers and association with surgeryinduced weight loss. J Clin Endocrinol Metab 99, E53-E61.
22. Lumeng CN, Deyoung SM, Bodzin JL et al. (2007) Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56, 16-23.
23. Serhan CN, Brain SD, Buckley CD et al. (2007) Resolution of inflammation: state of the art, definitions and terms. FASEB J 21, 325-332.
24. Tam CS, Clément K, Baur LA et al. (2010) Obesity and low-grade inflammation: a paediatric perspective. Obes Rev 11, 118-126.
25. Sbarbati A, Osculati F, Silvagni D et al. (2006) Obesity and inflammation: evidence for an elementary lesion. Pediatrics 117, 220-223.
26. Carolan E, Hogan AE, Corrigan M et al. (2013) The impact of childhood obesity on inflammation, innate immune cell frequency and metabolic microRNA expression. J Clin Endocrinol Metab Endocr Soc Chevy Chase 99, 474-478.
27. Apostolopoulos V, de Courten MPJ, Stojanovska L et al. (2015) The complex immunological and inflammatory network of adipose tissue in obesity. Mol Nutr Food Res 60, 43-57.
28. Greenberg AS &Obin MS (2006) Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 83, 461S-465S.
29. Zhu W, Cheng KKY, Vanhoutte PM et al. (2008) Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 114, 361-374.
30. Osborn O &Olefsky JM (2012) The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18, 363-374.
31. Andrade-Oliveira V, Câmara NOS &Moraes-Vieira PM (2015) Adipokines as drug targets in diabetes and underlying disturbances. J Diabetes Res 2015, 681612.
32. McArdle MA, Finucane OM, Connaughton RM et al. (2013) Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front Endocrinol 4, 52.
33. Harford KA, Reynolds CM, McGillicuddy FC et al. (2011) Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. Proc Nutr Soc 70, 408-417.
34. Lumeng CN, Bodzin JL &Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117, 175-184.
35. Gao Z, Hwang D, Bataille F et al. (2002) Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem 277, 48115-48121.
36. Emanuelli B, Peraldi P, Filloux C et al. (2000) SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275, 15985-15991.
37. Ueki K, Kondo T &Kahn CR (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24, 5434-5446.
38. Finucane OM, Lyons CL, Murphy AM et al. (2015) Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1β secretion and insulin resistance despite obesity. Diabetes 64, 2116-2128.
39. Martinon F, Burns K &Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10, 417-426.
40. Reynolds CM, McGillicuddy FC, Harford KA et al. (2012) Dietary saturated fatty acids prime the NLRP3 inflammasome via TLR4 in dendritic cells-implications for diet-induced insulin resistance. Mol Nutr Food Res 56, 1212-1222.
41. Jager J, Grémeaux T, Cormont M et al. (2007) Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 148, 241-251.
42. Gregor MF &Hotamisligil GS (2011) Inflammatory mechanisms in obesity. Ann Rev Immunol 29, 415-445.
43. Börgeson E &Godson C (2012) Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Front Immunol 3, 318.
44. Serhan CN &Savill J (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6, 1191-1197.
45. Serhan CN (2011) The resolution of inflammation: the devil in the flask and in the details. FASEB J 25, 1441-1448.
46. Calder PC, Ahluwalia N, Albers R et al. (2013) A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies. Br J Nutr 109 Suppl., S1-S34.
47. Gilroy DW, Lawrence T, Perretti M et al. (2004) Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 3, 401-416.
48. Titos E &Clària J (2013) Omega-3-derived mediators counteract obesity-induced adipose tissue inflammation. Prostaglandins Other Lipid Mediat 107, 77-84.
49. Börgeson E, Johnson AMF, Lee YS et al. (2015) Lipoxin A4 attenuates obesity-induced adipose inflammation and associated liver and kidney disease. Cell Metabolism 22, 125-137.
50. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444, 860-867.
51. Clària J, Dalli J, Yacoubian S et al. (2012) Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol 189, 2597-2605.
52. Lee JY, Sohn KH, Rhee SH et al. (2001) Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through toll-like receptor 4. J Biol Chem 276, 16683-16689.
53. Leamy AK, Egnatchik RA &Young JD (2013) Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res 52, 165-174.
54. Shi H, Kokoeva MV, Inouye K et al. (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116, 3015-3025.
55. Lee JY, Zhao L, Youn HS et al. (2004) Saturated fatty acid activates but polyunsaturated fatty acid inhibits toll-like receptor 2 dimerized with toll-like receptor 6 or 1. J Biol Chem 279, 16971-16979.
56. Lee JY, Plakidas A, Lee WH et al. (2003) Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res 44, 479-486.
57. Samuel VT, Liu Z-X, Wang A et al. (2007) Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 117, 739-745.
58. Blüher M, Bashan N, Shai I et al. (2009) Activated Ask1-MKK4-p38MAPK/JNK stress signaling pathway in human omental fat tissue may link macrophage infiltration to whole-body insulin sensitivity. J Clin Endocrinol Metab 94, 2507-2515.
59. Kim JK, Kim YJ, Fillmore JJ et al. (2001) Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108, 437-446.
60. Klein-Platat C, Drai J, Oujaa M et al. (2005) Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am J Clin Nutr 82, 1178-1184.
61. Phillips C (2013) Nutrigenetics and metabolic disease: current status and implications for personalised nutrition. Nutrients 5, 32-57.
62. Shen J, Arnett DK, Peacock JM et al. (2007) Interleukin1beta genetic polymorphisms interact with polyunsaturated fatty acids to modulate risk of the metabolic syndrome. J Nutr 137, 1846-1851.
63. Weldon SM, Mullen AC, Loscher CE et al. (2007) Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J Nutr Biochem 18, 250-258.
64. Honda KL, Lamon-Fava S, Matthan NR et al. (2014) EPA and DHA exposure alters the inflammatory response but not the surface expression of toll-like receptor 4 in macrophages. Lipids 50, 121-129.
65. Xue B, Yang Z, Wang X et al. (2012) Omega-3 polyunsaturated fatty acids antagonize macrophage inflammation via activation of AMPK/SIRT1 pathway. PLoS ONE 7, e45990.
66. Siriwardhana N, Kalupahana NS, Fletcher S et al. (2012) n-3 and n-6 polyunsaturated fatty acids differentially regulate adipose angiotensinogen and other inflammatory adipokines in part via NF-κB-dependent mechanisms. J Nutr Biochem 23, 1661-1667.
67. Oliver E, McGillicuddy FC, Harford KA et al. (2012) Docosahexaenoic acid attenuates macrophage-induced inflammation and improves insulin sensitivity in adipocytes-specific differential effects between LC n-3 PUFA. J Nutr Biochem 23, 1192-1200.
68. Feng D, Ling W-H &Duan R-D (2010) Lycopene suppresses LPS-induced NO and IL-6 production by inhibiting the activation of ERK, p38MAPK, and NF-kappaB in macrophages. Inflamm Res 59, 115-121.
69. Kim G, Kim J, Ahn S et al. (2004) Lycopene suppresses the lipopolysaccharide-induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and nuclear factor-jB. Immunology 113, 203-211.
70. Yang F, Oz HS, Barve S et al. (2001) The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factorkappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol 60, 528-533.
71. Landrier J-F, Gouranton E, El Yazidi C et al. (2009) Adiponectin expression is induced by vitamin E via a peroxisome proliferator-activated receptor gamma-dependent mechanism. Endocrinology 150, 5318-5325.
72. Lira FS, Rosa JC, Cunha CA et al. (2011) Supplementing alpha-tocopherol (vitamin E) and vitamin D3 in high fat diet decrease IL-6 production in murine epididymal adipose tissue and 3T3-L1 adipocytes following LPS stimulation. Lipids Health Dis 10, 37.
73. Wen H, Gris D, Lei Y et al. (2011) Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 12, 408-415.
74. Finucane OM, Reynolds CM, McGillicuddy FC et al. (2014) Macrophage migration inhibitory factor deficiency ameliorates high-fat diet induced insulin resistance in mice with reduced adipose inflammation and hepatic steatosis. PLoS ONE 9, e113369.
75. Ferrucci L, Cherubini A, Bandinelli S et al. (2006) Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 91, 439-446.
76. Lopez-Garcia E, Schulze MB, Manson JE et al. (2004) Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr 134, 1806-1811.
77. van Herpen-Broekmans WMR, Klöpping-Ketelaars IAA, Bots ML et al. (2004) Serum carotenoids and vitamins in relation to markers of endothelial function and inflammation. Eur J Epidemiol 19, 915-921.
78. Ramel A, Martinez JA, Kiely M et al. (2010) Effects of weight loss and seafood consumption on inflammation parameters in young, overweight and obese European men and women during 8 weeks of energy restriction. Eur J Clin Nutr 64, 987-993.
79. Browning LM, Krebs JD, Moore CS et al. (2007) The impact of long chain n-3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. Diab Obes Metab 9, 70-80.
80. Skulas-Ray AC, Kris-Etherton PM, Harris WS et al. (2011) Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 93, 243-252.
81. Kelley DS, Siegel D, Fedor DM et al. (2009) DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr 139, 495-501.
82. Satoh N, Shimatsu A, Kotani K et al. (2009)Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens Res 32, 1004-1008.
83. Tierney AC, McMonagle J, Shaw DI et al. (2011) Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome-LIPGENE: a European randomized dietary intervention study. Int J Obes (Lond) 35, 800-809.
84. López-Alarcón M, Martínez-Coronado A, Velarde-Castro O et al. (2011) Supplementation of n3 long-chain polyunsaturated fatty acid synergistically decreases insulin resistance with weight loss of obese prepubertal and pubertal children. Arch Med Res 42, 502-508.
85. Nobili V, Bedogni G, Alisi A et al. (2011) Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 96, 350-353.
86. Dangardt F, Osika W, Chen Y et al. (2010) Omega-3 fatty acid supplementation improves vascular function and reduces inflammation in obese adolescents. Atherosclerosis 212, 580-585.
87. Pedersen MH, Mølgaard C, Hellgren LI et al. (2011) The effect of dietary fish oil in addition to lifestyle counselling on lipid oxidation and body composition in slightly overweight teenage boys. J Nutr Metab 2011, 348368.
88. López-Vicario C, Rius B, Alcaraz-Quiles J et al. (2015) Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases. Eur J Pharmacol (In the Press).
89. Molendi-Coste O, Legry V &Leclercq IA (2011) Why and how meet n-3 PUFA dietary recommendations? Gastroenterol Res Pract 2011, 364040.
90. Hudert CA, Weylandt KH, Lu Y et al. (2006) Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 103, 11276-11281.
91. White PJ, Arita M, Taguchi R et al. (2010) Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesitylinked inflammation and insulin resistance in high-fat-fed mice. Diabetes 59, 3066-3073.
92. Mas E, Croft KD, Zahra P et al. (2012) Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 58, 1476-1484.
93. Bannenberg GL (2009) Resolvins: current understanding and future potential in the control of inflammation. Curr Opin Drug Discov Dev 12, 644-658.
94. Lopategi A, López-Vicario C, Alcaraz-Quiles J et al. (2015) Role of bioactive lipid mediators in obese adipose tissue inflammation and endocrine dysfunction. Mol Cell Endocrinol 419, 44-59.
95. Song Y, Cook NR, Albert CM et al. (2009) Effects of vitamins C and E and beta-carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: a randomized controlled trial. Am J Clin Nutr 90, 429-437.
96. Thies F, Masson LF, Rudd A et al. (2012) Effect of a tomato-rich diet on markers of cardiovascular disease risk in moderately overweight, disease-free, middle-aged adults: a randomized controlled trial. Am J Clin Nutr 95, 1013-1022.
97. Wu JHY, Ward NC, Indrawan AP et al. (2007) Effects of alpha-tocopherol and mixed tocopherol supplementation on markers of oxidative stress and inflammation in type 2 diabetes. Clin Chem 53, 511-519.
98. Yang F, DeVilliers WJ, McClain CJ et al. (1998) Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. Am Soc Nutr Sci 128, 2334-2340.
99. Ghavipour M, Saedisomeolia A, Djalali M et al. (2012) Tomato juice consumption reduces systemic inflammation in overweight and obese females. Br J Nutr 109, 2031-2035.
100. McEneny J, Wade L, Young IS et al. (2012) Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals. J Nutr Biochem 1, 1-6.
101. Basu A, Du M, Sanchez K et al. (2011) Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome. Nutrition 27, 206-213.
102. Codoñer-Franch P, López-Jaén AB, De La Mano-Hernández A et al. (2010) Oxidative markers in children with severe obesity following low-calorie diets supplemented with mandarin juice. Acta Paediatr 99, 1841-1846.
103. Murer SB, Aeberli I, Braegger CP et al. (2014) Antioxidant supplements reduced oxidative stress and stabilized liver function tests but did not reduce inflammation in a randomized controlled trial in obese children and adolescents. J Nutr 144, 193-201.
104. Donath MY (2014) Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 13, 465-476.
105. Esser N, Paquot N &Scheen AJ (2015) Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs 24, 283-307.
106. Minihane AM, Vinoy S, Russell WR et al. (2015) Lowgrade inflammation, diet composition and health: current research evidence and its translation. Br J Nutr 114, 999-1012.
107. Bakker GCM, van Erk MJ, Pellis L et al. (2010) An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men : a nutrigenomics approach. Am J Clin Nutr 91, 1044-1059.
108. Holmes E, Wilson ID &Nicholson JK (2008) Metabolic phenotyping in health and disease. Cell 134, 714-717.
109. Holmes E, Wijeyesekera A, Taylor-Robinson SD et al. (2015) The promise of metabolic phenotyping in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 12, 458-471.
110. Phillips CM, Dillon C, Harrington JM et al. (2013) Defining metabolically healthy obesity: role of dietary and lifestyle factors. PLoS ONE 8, e76188.
111. Phillips CM, Kesse-Guyot E, Ahluwalia N et al. (2012) Dietary fat, abdominal obesity and smoking modulate the relationship between plasma complement component 3 concentrations and metabolic syndrome risk. Atherosclerosis 220, 513-519.
112. Wopereis S, Rubingh CM, van Erk MJ et al. (2009) Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes. PLoS ONE 4, e4525.
113. Matone A, O'Grada CM, Dillon ET et al. (2015) Body mass index mediates inflammatory response to acute dietary challenges. Mol Nutr Food Res 59, 2279-2292.
114. Daniele G, Guardado Mendoza R, Winnier D et al. (2014) The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51, 123-131.
115. Recasens M, López-Bermejo A, Ricart W et al. (2005) An inflammation score is better associated with basal than stimulated surrogate indexes of insulin resistance. J Clin Endocrinol Metab 90, 112-116.
116. Duncan BB, Schmidt MI, Pankow JS et al. (2003) Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52, 1799-1805.